Bioenvision to Hold Fiscal 2007 Second Quarter Financial Results Conference Call on Thursday, February 8, 2007
January 31 2007 - 12:12PM
Business Wire
Bioenvision Inc. (NasdaqGM:BIVN) will hold a live webcast of its
quarterly conference call at 10:00a.m. EST on Thursday, February
8th, 2007. Jim Scibetta, Chief Financial Officer, will host the
call. Senior management will discuss the Company�s financial
results as of December 31, 2006, the progress towards its goals,
and additional corporate activities, including the EMeA filing for
Evoltra� in adult acute myeloid leukemia (AML). Bioenvision will
announce the highlights of these topics in a press release to be
issued before the market opens on February 8, 2007, prior to the
conference call. Conference Call Information: Date: 2/8/07 Time:
10:00a.m. Eastern Standard Time Toll free (US & Canada):
866-585-6398 International: 416-849-9626 Webcast:
www.bioenvision.com A replay of the call and webcast will be
available for 14 days. Replay number (US & Canada):
866-245-6755 Replay number international: 416-915-1035 Replay
passcode: 752762 Webcast replay: www.bioenvision.com About
Bioenvision Bioenvision's primary focus is the acquisition,
development and marketing of compounds and technologies for the
treatment of cancer. Bioenvision has a broad pipeline of products
for the treatment of cancer, including: Evoltra�, Modrenal� (for
which Bioenvision has obtained regulatory approval for marketing in
the United Kingdom for the treatment of post-menopausal breast
cancer following relapse to initial hormone therapy), and other
products. Bioenvision is also developing anti-infective
technologies, including the OLIGON� technology; an advanced
biomaterial that has been incorporated into various FDA approved
medical devices and Suvus�, an antimicrobial agent currently in
clinical development for refractory chronic hepatitis C infection.
For more information on Bioenvision please visit our Web site at
www.bioenvision.com. Certain statements contained herein are
"forward-looking" statements (as such term is defined in the
Private Securities Litigation Reform Act of 1995). Because these
statements include risks and uncertainties, actual results may
differ materially from those expressed or implied by such
forward-looking statements. Specifically, factors that could cause
actual results to differ materially from those expressed or implied
by such forward-looking statements include, but are not limited to:
risks associated with preclinical and clinical developments in the
biopharmaceutical industry in general and in Bioenvision's
compounds under development in particular; the potential failure of
Bioenvision's compounds under development to prove safe and
effective for treatment of disease; uncertainties inherent in the
early stage of Bioenvision's compounds under development; failure
to successfully implement or complete clinical trials; failure to
receive marketing clearance from regulatory agencies for our
compounds under development; acquisitions, divestitures, mergers,
licenses or strategic initiatives that change Bioenvision's
business, structure or projections; the development of competing
products; uncertainties related to Bioenvision's dependence on
third parties and partners; and those risks described in
Bioenvision's filings with the SEC. Bioenvision disclaims any
obligation to update these forward-looking statements.
Bioenvision (NASDAQ:BIVN)
Historical Stock Chart
From Jun 2024 to Jul 2024
Bioenvision (NASDAQ:BIVN)
Historical Stock Chart
From Jul 2023 to Jul 2024